| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/10000 | Human,Mouse,Rat |
| Aliases | KIAK0002 |
| WB Predicted band size | 33 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CCND2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CCND2抗体的3篇参考文献示例(注意：以下内容为模拟示例，具体文献需通过学术数据库检索获取)：
---
1. **文献名称**：*Cyclin D2 expression in human cancers: a systematic review using antibody-based detection*
**作者**：Smith A, et al.
**摘要**：本研究通过免疫组化(IHC)和Western blot技术，分析了CCND2蛋白在多种癌症组织中的表达差异。结果显示，CCND2在乳腺癌和结直肠癌中高表达，并与患者预后不良相关。研究验证了所用抗体的特异性，确认其适用于临床样本检测。
---
2. **文献名称**：*Development and validation of a monoclonal antibody for CCND2 in cell cycle studies*
**作者**：Lee B, et al.
**摘要**：文章报道了一种新型抗CCND2单克隆抗体的开发过程，通过ELISA和免疫荧光验证其高特异性。该抗体成功应用于细胞周期分析，证明CCND2在G1/S期转换中起关键作用，并揭示了其在肿瘤细胞增殖中的调控机制。
---
3. **文献名称**：*CCND2 knockdown suppresses hepatocellular carcinoma progression: insights from antibody-mediated protein detection*
**作者**：Wang C, et al.
**摘要**：研究利用siRNA敲低CCND2基因，结合特异性抗体检测蛋白表达变化，发现CCND2下调可抑制肝癌细胞增殖和迁移。实验进一步通过流式细胞术证实CCND2缺失导致细胞周期阻滞，提示其作为肝癌治疗靶点的潜力。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“CCND2 antibody”、“cyclin D2 antibody”并结合研究场景(如癌症、实验方法)筛选。
The CCND2 antibody is a crucial tool for studying Cyclin D2. a protein encoded by the *CCND2* gene, which plays a pivotal role in regulating the cell cycle. Cyclin D2 belongs to the D-type cyclin family and functions as a regulatory subunit of cyclin-dependent kinases (CDK4/6), driving the G1-to-S phase transition by phosphorylating retinoblastoma (Rb) proteins. This process is essential for cell proliferation, differentiation, and tissue development. Dysregulation of CCND2 expression is implicated in various cancers (e.g., lymphomas, breast cancer) and developmental disorders, making it a biomarker of interest in oncology and biomedical research.
CCND2 antibodies are typically raised against specific epitopes of the Cyclin D2 protein, enabling detection and quantification in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry. These antibodies help elucidate CCND2's expression patterns, post-translational modifications, and interactions with CDKs or inhibitors (e.g., p21. p27). Researchers also use CCND2 antibodies to explore its role in diseases, such as its overexpression in certain tumors or reduced levels in conditions like primary ovarian insufficiency. Validated antibodies are critical for ensuring specificity, minimizing cross-reactivity with homologous cyclins (D1/D3), and supporting translational studies targeting cell cycle pathways for therapeutic intervention.
×
